Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Tax Provisions (2024 - 2025)

Silence Therapeutics' Tax Provisions history spans 2 years, with the latest figure at $1000.0 for Q3 2025.

  • On a quarterly basis, Tax Provisions fell 97.96% to $1000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $11000.0, a 98.7% decrease, with the full-year FY2025 number at $11000.0, down 98.7% from a year prior.
  • Tax Provisions hit $1000.0 in Q3 2025 for Silence Therapeutics, down from $10000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for SLN hit a ceiling of $324000.0 in Q4 2024 and a floor of $1000.0 in Q3 2025.